177 related articles for article (PubMed ID: 9676845)
1. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
2. Predictive performance of a pharmacodynamic model for oral etoposide.
Miller AA; Tolley EA
Cancer Res; 1994 Apr; 54(8):2080-3. PubMed ID: 8174108
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.
Miller AA; Tolley EA; Niell HB; Griffin JP; Mauer AM
J Clin Oncol; 1993 Jun; 11(6):1179-88. PubMed ID: 8388920
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
9. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
10. [Prolonged oral etoposide therapy in advanced stage lung cancer].
Bozóky G; Ruby E; Góhér I; Mohos A; Lengyel M
Orv Hetil; 1997 Jul; 138(28):1791-5. PubMed ID: 9280873
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
[TBL] [Abstract][Full Text] [Related]
12. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract][Full Text] [Related]
13. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
14. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
Felip E; Massuti B; Camps C; Benito D; Isla D; González-Larriba JL; López-Cabrerizo MP; Salamanca O; Puerto-Pica J; Moyano A; Baselga J; Rosell R
Clin Cancer Res; 1998 Nov; 4(11):2723-8. PubMed ID: 9829735
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
17. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
Isobe T; Fukuoka M; Negoro S; Sugiura T; Kawahara M; Kudoh S; Araki J; Nakagawa K; Yokozaki M; Yamakido M; Ariyoshi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
19. [Long-term oral administration of etoposide in the treatment of patients with advanced non-small-cell carcinoma of the lung. The second phase of a clinical study].
Jeremić B; Djurić Lj; Jevremović S; Stefanović K; Matović M
Srp Arh Celok Lek; 1996; 124(3-4):65-8. PubMed ID: 9102821
[TBL] [Abstract][Full Text] [Related]
20. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
